Physician profile
Marcela Abuid
NPI 1801945613
$2,616.68
in general payments reported to CMS, 2019-2025
21 companies · $992 in 2025
The $992 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $92.38 · 2021: $98.89 · 2022: $375 · 2023: $263 · 2024: $567 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.85 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $584.62 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $368.49 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.74 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $313.75 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $233.09 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $108.33 | 2019-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Pulmonx Corporation | $83.10 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Takeda Pharmaceuticals U.S.A., INC. | $63.42 | 2024-2025 | Glassia, Aralast |
| Actelion Pharmaceuticals US, INC. | $55.71 | 2019-2025 | Opsumit |
| Merck Sharp & Dohme LLC | $52.35 | 2025 | Winrevair |
| Philips North America LLC | $49.02 | 2023-2024 | (Ck4) Mcot |
| United Therapeutics Corporation | $47.90 | 2023-2024 | Tyvaso |
| Grifols USA, LLC | $42.66 | 2019-2020 | |
| Medtronic, INC. | $33.19 | 2024 | Illumisite |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $31.74 | 2025 | Arikayce |
| Viatris Specialty LLC | $27.32 | 2025 | Yupelri |
| Genentech USA, INC. | $22.15 | 2023 | Xolair |
| Shire North American Group INC | $18.14 | 2019 | |
| Baxter Healthcare | $15.55 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Janssen Pharmaceuticals, INC | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcela Abuid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.